01—Abstract
Summary
Summary of the 10-K filed February 25, 2011. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. reported solid performance in its 2010 10-K filing, with total revenues reaching $15.05 billiona, a 3% increase from the previous year.
The company's principal products—Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, and Enbrel®—continued to be the primary revenue drivers, collectively accounting for approximately 91%b of sales in 2010. A significant development highlighted is the launch of Prolia® and XGEVA™ in 2010, representing new growth opportunities. However, Amgen faces ongoing challenges, particularly concerning its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®, due to increased regulatory scrutiny, revised product labeling, and changes in reimbursement policies like the Medicare bundled payment system for dialysis.
The company also faces increasing competition from biosimilars in Europe and anticipates similar pressures in the U.S. following the introduction of biosimilar pathways. Amgen remains focused on expanding its pipeline and managing its operational costs effectively amidst these evolving market dynamics.
02—Key points
Key Highlights
- Total revenues for 2010 reached $15.05 billion, a 3% increase year-over-year, driven by growth in key products.
- The company launched Prolia® and XGEVA™ in 2010, introducing new therapeutic options and growth avenues.
- Principal products (Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, Enbrel®) generated 91% of total revenues in 2010, underscoring their importance.
- Amgen is navigating significant regulatory and reimbursement challenges for its ESA products (Aranesp® and EPOGEN®), including updated labeling and Medicare policy changes.
- Increased competition from biosimilars in Europe is noted, with anticipation of similar trends in the U.S. market.
- The company continues to invest heavily in Research & Development, with R&D expenses totaling $2.89 billion in 2010.
- Amgen repurchased $3.8 billion of its common stock in 2010, signaling confidence in its financial position and a return of capital to shareholders.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 25, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $15.05B$14.64B | +2.8% |
| SG&A Expenses | $3.98B$3.82B | +4.3% |
| Operating Expenses | $9.51B$9.14B | +4.1% |
| Operating Income | $5.54B$5.51B | +0.7% |
| Interest Expense | $604.00M$578.00M | +4.5% |
| Net Income | $4.63B$4.61B | +0.5% |
| EPS (Basic) | $4.82$4.53 | +6.4% |
| EPS (Diluted) | $4.79$4.51 | +6.2% |
| Shares Outstanding (Basic) | 960.00M1.02B | −5.5% |
| Shares Outstanding (Diluted) | 965.00M1.02B | −5.5% |
05—Questions
Frequently Asked Questions
What were Amgen's main revenue sources in 2010?
Amgen's primary revenue sources in 2010 were its principal products: Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim), and Enbrel® (etanercept). These products accounted for approximately 91% of the company's total revenue for the year.
What significant new products did Amgen launch in 2010?
In 2010, Amgen launched Prolia® (denosumab) for osteoporosis and XGEVA™ (denosumab) for the prevention of skeletal-related events in cancer patients. These launches represent important new opportunities for the company.
What are the key challenges Amgen faces regarding its ESA products?
Amgen faces several challenges with its ESA products, Aranesp® and EPOGEN®. These include increased regulatory scrutiny from bodies like the FDA and CMS, revised product labeling due to safety concerns, and changes in reimbursement policies. For example, the Medicare bundled payment system for dialysis effective January 1, 2011, is expected to negatively impact EPOGEN® sales, and ongoing reviews by CMS for ESAs in kidney disease patients could affect future coverage and reimbursement.
How is Amgen addressing competition from biosimilars?
Amgen acknowledges increasing competition from biosimilars in Europe and anticipates similar trends in the U.S. market following the introduction of the abbreviated pathway for biosimilar approvals under the healthcare reform legislation. The company's strategy involves leveraging its patent portfolio and focusing on the innovation and quality of its biologic products to maintain its competitive position.
06—Continue